News

News Center

Warmly celebrating Jiuzhitang Maker for winning the Grand Prize at the Tsinghua Alumni Global Finals in Health and Medical Innovation!

2024-10-22

From October 16 to 18, 2024, the 9th Tsinghua Alumni Triple Innovation Competition Global Finals in Health & Medical Technology, hosted by the Tsinghua Alumni Association and the Management Committee of the Yixing Environmental Protection Science & Technology Industrial Park in China, was successfully held in Yixing, Jiangsu Province.

Jiuzhitang Maker’s "Mesenchymal Stem Cell Drug Development Project" advanced through multiple rounds of competition in the regional qualifiers and successfully earned a spot in this year’s global finals. Standing out with its cutting-edge, innovative technology, the project was awarded the Champion Prize in the Angel Growth Category.

The Tsinghua Alumni Triple Innovation Competition was launched in 2016. Organized by the Tsinghua Alumni Association, it’s a large-scale, multi-level, and continuous series of events designed to provide comprehensive support for alumni, faculty, students, and individuals from various sectors of society who are passionate about "creative, innovative, and entrepreneurial" endeavors. The competition is divided into seven distinct industry tracks and has so far successfully connected over 5,000 alumni-led startup projects. This year’s Global Finals in the Health & Medical sector brought together 53 cutting-edge innovation projects, competing across two categories: the Seed Group and the Angel Growth Group.

Dr. Gao Yansong, General Manager of Jiuzhitang Maker and an alumnus of Tsinghua University, represented the company at the final pitch event. During the presentation, Dr. Gao provided a detailed overview of Jiuzhitang Maker’s corporate vision, strategic direction, and the innovative, cutting-edge, and unique features of the company’s products and technologies—earning high praise and unanimous approval from the experts at the Tsinghua Triple Innovation Competition.

Jiuzhitang Maker’s expansion technology enables the production of up to 10 million mesenchymal stem cell products from bone marrow tissue sourced from a single donor, pioneering the industry by addressing the critical bottleneck that has long hindered the development of stem cell-based therapies. Their unique hypoxic production process mimics the body’s natural microenvironment, resulting in stem cells with enhanced homing, proliferation, and tissue-repair capabilities. Additionally, Jiuzhitang Maker has established a comprehensive quality management system covering the entire lifecycle of its pharmaceutical products, successfully earning ISO9001, ISO14001, and ISO4500 certifications, as well as the China Association for Medical Biotechnology’s self-regulatory certification for quality management in stem cell preparation. The company has also obtained the CNAS accreditation and received a qualified inspection report from the China National Institute for Food and Drug Control.

As of now, Jiuzhitang Maker has two stem-cell-based new drugs approved and already entering clinical trials, targeting ischemic stroke and autoimmune alveolar proteinosis, respectively. The company is also actively pursuing research in several other challenging diseases, including psychiatric disorders, orthopedic conditions, dermatological issues, and cardiovascular diseases. Throughout this competition, the powerful force of innovation shone brightly, consistently inspiring and influencing one another across all activities.

As a national high-tech enterprise, Jiuzhitang Maker will always uphold its spirit of innovation by establishing a stem cell CQDMO service platform. We are committed to providing industry-leading companies and research institutions with end-to-end, customized stem cell CQDMO services tailored to their specific needs. At the same time, Jiuzhitang Maker will continue to strengthen collaboration and knowledge exchange across various sectors of the industry, leveraging our advanced manufacturing technologies and robust industrialization capabilities to accelerate the launch of stem cell-based therapies in the domestic market.

Sichuan Free Trade Zone: Striving to convert cell and gene therapies that meet medical technology access standards into approved healthcare service pricing items as per regulations.

Shanghai provides comprehensive, end-to-end support for biopharmaceutical development, with each entity eligible to receive cumulative annual funding of up to 100 million yuan.

Here is the title—h1 placeholder text

Online Message

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business license